Impetigo Treatment Misses Ph II Endpoint

NovaBay Pharmaceuticals completed its Phase IIb clinical study of auriclosene in the treatment of impetigo. While the study showed that auriclosene is safe and well tolerated, it did not meet its primary clinical endpoint. NovaBay and development partner Galderma are examining the results from this study and expect to use the findings to guide the future course of the clinical development for auriclosene. NovaBay expects to provide an update in the near future.

Under the terms of an exclusive licensing agreement, Galderma is responsible for the clinical development for auriclosene for impetigo. The agreement is global in scope and provides Galderma with an option for Galderma to license auriclosene for use in other dermatological indications